Skip Navigation

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center

  1. Roy F. Chemaly3
  1. 1Division of Pharmacy
  2. 2Department of Laboratory Medicine
  3. 3Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center
  4. 4Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Texas
  5. 5JMI Laboratories, North Liberty, Iowa
  1. Correspondence: R. F. Chemaly, Department of Infectious Diseases, Infection Control, and Employee Health (Unit 1460), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (rfchemaly{at}mdanderson.org).

Abstract

Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.

Key words

  • Received April 29, 2016.
  • Accepted June 8, 2016.
| Table of Contents

Published on behalf of

cid cover HIV Medicine Association Logo

Society Members: For your free access to this journal, log in via the IDSA members area.

Impact Factor: 8.886

5-Yr impact factor: 9.206

For Reviewers

Looking for your next opportunity?

Looking for jobs...

For the Media

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.